$ query --field literature --order chronological
PT-141 Research: From Hypothalamic Neurons to Phase 3
The mechanism studies, the pivotal trials, the long-term extension, and the negative findings — each result attributed to its study.
The gist
PT-141 research runs from animal pharmacology in the early 2000s to two large human trials and an FDA approval in 2019. The early studies established the mechanism: PT-141, a synthetic alpha-MSH analogue, switches on melanocortin receptors (MC3R/MC4R) in the brain, produced erections in rats and primates, activated hypothalamic neurons, and produced dose-dependent erectile activity in men [1]. Female-rat work then showed it selectively increases desire-driven behavior [2]. The human story peaks with RECONNECT, two identical Phase 3 trials in premenopausal women with HSDD that supported approval [3], plus a 52-week safety extension [4] and a brain-imaging study explaining the central mechanism [5]. A 2025 hamster study adds a careful negative finding about the reward circuit [6]. The FDA label anchors the dose, pharmacokinetics, and warnings [7]. This page walks that record study by study; the full citations live on the PT-141 references page.
Mechanism and preclinical foundation
The foundational pharmacology was set out by Molinoff and colleagues: PT-141 is an agonist at melanocortin receptors (MC3R/MC4R) expressed primarily in the central nervous system, and systemic administration produced penile erections in rats and nonhuman primates while increasing c-Fos (a marker of neuronal activation) in the hypothalamus — and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. Pfaus and colleagues then showed in female rats that PT-141 selectively stimulated appetitive, solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity — evidence that central melanocortin systems help regulate female sexual desire, and the first pharmacological agent reported to act on appetitive female sexual behavior [2]. A broader review situated bremelanotide within melanocortin pharmacology for male and female sexual dysfunction [11].
The Phase 3 RECONNECT trials
The pivotal evidence is two identical Phase 3 randomized controlled trials — RECONNECT — enrolling 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg given subcutaneously as needed met both coprimary endpoints: a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. The most common adverse events were nausea, flushing, and headache [3]. A 52-week open-label extension enrolled 684 women and found no new safety signals, with sustained desire improvements; the most common drug-related treatment-emergent events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. An accessible approval-era review summarized the same pharmacology, efficacy, dosing, and adverse-event data [12].
Brain imaging and a careful negative finding
A randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD provided mechanistic human evidence: MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing — enhanced amygdala-insula functional connectivity and cerebellar/supplementary-motor activity — in response to erotic stimuli [5]. Balancing the picture, a 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in ventral tegmental area dopamine neurons, but reported that neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA expression in the mesolimbic dopamine system, and that bremelanotide did not enhance sexual reward in a conditioned-place-preference test — suggesting it does not act on the VTA-nucleus accumbens reward circuit [6]. Good research includes its negative results.
Regulatory context and the open questions
Bremelanotide received its first regulatory approval in the United States in June 2019 for HSDD in premenopausal women, as a 1.75 mg subcutaneous as-needed injection [10]. Its approval landed in a strong year for peptide drugs — a 2019 review of FDA-approved peptide and oligonucleotide therapeutics situates it within that broader trend [9]. The US prescribing information is the authoritative source for dose, pharmacokinetics, and warnings [7]. The open questions are explicit: independent re-analyses argue the trial effects are small; nausea drives discontinuation; transient blood-pressure increases shape the contraindications; and uses in men, postmenopausal women, and for performance remain off-label or unapproved. The compound is well-characterized for one indication and lightly characterized for the rest.